Design of a Tetracycline Operon Inducible System for the Control of Vaccinia Virus Replication: Implications for Vaccine Development by Hagen, Caitlin J
University of Connecticut
OpenCommons@UConn
Master's Theses University of Connecticut Graduate School
12-18-2011
Design of a Tetracycline Operon Inducible System
for the Control of Vaccinia Virus Replication:
Implications for Vaccine Development
Caitlin J. Hagen
caitlinjhagen@gmail.com
This work is brought to you for free and open access by the University of Connecticut Graduate School at OpenCommons@UConn. It has been
accepted for inclusion in Master's Theses by an authorized administrator of OpenCommons@UConn. For more information, please contact
opencommons@uconn.edu.
Recommended Citation
Hagen, Caitlin J., "Design of a Tetracycline Operon Inducible System for the Control of Vaccinia Virus Replication: Implications for
Vaccine Development" (2011). Master's Theses. 198.
https://opencommons.uconn.edu/gs_theses/198
  
Design of a Tetracycline Operon Inducible System for the Control of 
Vaccinia Virus Replication: Implications for Vaccine Development 
 
 
 
 
 
Caitlin J. Hagen 
 
B.A., Ohio Wesleyan University, 2009 
 
 
 
 
A Thesis 
Submitted in Partial Fulfillment of the 
Requirements for the Degree of 
Master of Science 
at the 
University of Connecticut 
2011 
  ii 
APPROVAL PAGE 
 
Master of Science Thesis 
 
Design of a Tetracycline Operon Inducible System for the Control of 
Vaccinia Virus Replication: Implications for Vaccine Development 
 
 
Presented by  
Caitlin J. Hagen, B.A 
 
 
Major Advisor_________________________________________________ 
Paulo H. Verardi 
 
Associate Advisor______________________________________________ 
Guillermo R. Risatti 
 
Associate Advisor______________________________________________ 
Antonio E. Garmendia 
 
University of Connecticut 
2011 
  iii 
ACKNOWLEDGEMENTS 
 
I am extremely grateful to my major advisor Dr. Paulo Verardi for his constant 
support and mentorship throughout my graduate program.  I have learned  a great deal 
through my experience as a master’s student and my enthusiasum and interest in virology 
and vaccine design has only continued to increase.  I would also like to thank the 
members of my committee Dr. Guillermo Risatti and Dr. Antonio Garmendia for their 
guidence and advice in support of my graduate thesis. 
I am also grateful to my fellow laboratory member, Alisson Titong, for all her 
help and constructive thoughts throughout this work.  I would like to thank John 
Sopronyi for his work with vaccinia virus promoters and his design of the synthetic early 
promoter.  I offer thanks to the members of the Verardi laboratory for their support and 
interest in my work.   
I would also like to thank the Department of Pathobiology at the University of 
Connecticut for the resources and support of the department members I have had over the 
past few years.  Lastly I would like to thank my family and friends for their 
encouragement and moral support throughout my graduate studies. 
 
  iv 
TABLE OF CONTENTS 
 
Title Page ............................................................................................................................ i 
Approval Page ................................................................................................................... ii 
Acknowledgements .......................................................................................................... iii 
Table of Contents .............................................................................................................. iv 
Abstract ............................................................................................................................ vi 
 
CHAPTER 1: INTRODUCTION ................................................................................ 1 
1.1. Vaccinia Virus and Smallpox .............................................................................. 2 
1.2. Vaccinia Virus as a Vector ................................................................................... 2 
1.3. Adverse Events Associated with the Smallpox Vaccine ..................................... 4 
1.4. Treatment of Adverse Events ............................................................................... 4 
1.5. Contraindications for Smallpox Vaccination ....................................................... 5 
1.6. Current Status of Smallpox Vaccination in the United States ............................. 6 
1.7. New Generation Smallpox Vaccines ................................................................... 7 
1.8. Hypothesis ............................................................................................................ 9 
1.9. Significance of Proposed Work ............................................................................10 
1.10. Inducible Vaccinia Virus Systems ..................................................................... 11 
1.11. The Tetracycline Operon ....................................................................................13 
1.12. Tetracyclines ...................................................................................................... 14 
1.13. Vaccinia Virus Replication ................................................................................ 15 
 
  v 
CHAPTER 2: USE OF VACCINIA VIRUS EARLY D1R GENE TO CONTROL 
VIRAL REPLICATION ......................................................................17 
2.1. Introduction .......................................................................................................... 18 
2.2. Materials and Methods ......................................................................................... 20 
2.3. Results .................................................................................................................. 25 
2.4. Discussion ............................................................................................................ 26 
 
CHAPTER 3: IMPROVEMENT OF TRANSFER VECTORS ............................... 28 
3.1. Introduction .......................................................................................................... 29 
3.2. Materials and Methods ......................................................................................... 30 
3.3. Results .................................................................................................................. 33 
3.4. Discussion ............................................................................................................ 34 
 
CHAPTER 4: USE OF VACCINIA VIRUS LATE GENES TO CONTROL 
VIRUS REPLICATION ...................................................................... 36 
4.1. Introduction .......................................................................................................... 37 
4.2. Materials and Methods ......................................................................................... 45 
4.3. Results .................................................................................................................. 55 
4.4. Discussion ............................................................................................................ 65 
 
CONCLUSIONS AND FUTURE DIRECTIONS ....................................................... 71 
 
LITERATURE CITED .................................................................................................. 74 
  vi 
ABSTRACT 
 
The use of vaccinia virus (VACV) as a vaccine resulted in the eradication of 
smallpox in 1979.  Characteristics that contribute to the effectiveness of VACV as a 
vaccine and viral vector include its ability to elicit strong, long-lived humoral and cell-
mediated immune responses as a live-replicating virus and to accept large inserts of DNA 
into its genome.  However, adverse events associated with its use as the smallpox vaccine 
have constrained it from being more widely utilized in vaccines and therapies.  We 
propose to improve the safety of VACV as a live-replicating vector by using elements of 
the tet operon to control transcription of VACV genes essential for virus growth.  This 
would allow viral replication to be regulated through the addition or removal of 
tetracyclines.  Seven VACV genes were tested in an attempt to control viral replication. 
For each gene a different recombinant was generated in which the essential gene was 
placed under the control of tet operon elements.  Of the seven VACV genes tested, 
recombinants utilizing the A6L, A7L, D6R, and F17R genes were successful in 
regulating viral replication with tetracyclines. 
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CHAPTER 1:  INTRODUCTION 
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1.1.  VACCINIA VIRUS AND SMALLPOX 
Vaccinia virus (VACV) is the prototypical member of the family Poxviridae, 
genus Orthopoxvirus.  This genus also includes cowpox virus, monkeypox virus, and 
most notably variola virus, the causative agent of smallpox.  Smallpox was an extremely 
devastating disease that affected the world for thousands of years.  Efforts to protect 
against this disease lead to the development of vaccination.  The earliest reports of 
attempts to protect against smallpox come from China in the 10th century, where 
variolation by insufflation was practiced (Fenner, 1988).  People would be deliberately 
inoculated with smallpox from the pustules of patients that had the active disease.  This 
practice decreased the fatality rate from 20-30% to 0.5%-2.0% (Fenner, 1988).  It was not 
until after 1798, when Jenner discovered that cowpox was able to protect against 
smallpox, that modern vaccination practices began.  Overtime VACV replaced cowpox 
virus as the vaccine agent; even though the origin of VACV is uncertain, it is genetically 
distinct from both variola and cowpox virus.  The use of VACV as the smallpox vaccine 
was eventually responsible for the eradication of smallpox, declared in 1979 by the 
World Health Organization (WHO) (Wehrle, 1980). 
 
1.2.  VACCINIA VIRUS AS A VECTOR 
VACV has been developed as an expression vector, allowing heterologous 
(foreign) genes to be expressed by the virus.  Recombinant gene expression using VACV 
was first accomplished in 1982 when the herpesvirus thymidine kinase (TK) gene was 
inserted into a TK- VACV strain, giving the recombinant a TK+ phenotype (Mackett, et 
al., 1982, Panicali and Paoletti, 1982).  The flexibility of VACV for accepting foreign 
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DNA was tested by inserting 25 kb of bacteriophage λ DNA into the VACV TK gene, 
thus determining that VACV is capable of forming stable, infectious, and replication 
competent recombinants with as much as 25 kb of foreign DNA (Smith and Moss, 1983).  
VACV expression vectors can be used to study protein structure, function, and 
processing, as well as to develop recombinant vaccines where the heterologous expressed 
gene is used to elicit immune responses (Carroll and Moss, 1997).  The extensive 
characterization of VACV, along with its ability to elicit strong humoral and cell-
mediated immune responses as a live replicating virus and accept large inserts of DNA 
into its genome, makes it an ideal viral vector (Bennink, et al., 1984).  VACV has been 
successfully used in rabies and rinderpest vaccines, leading to better control of these 
diseases (Slate, et al., 2009, Verardi, et al., 2002).  Another feature of VACV that makes 
it an appealing vector is its ability to infect a wide range of cells, including different 
tumors.  The immunogenicity of VACV combined with its broad tumor tissue tropism 
can be used to enhance host immunity against tumor cells (Mullen and Tanabe, 2002).  
This allows VACV to be used as an oncolytic vector and to be used in immunotherapies 
for cancer treatment (Jager, et al., 2006, Kaufman, et al., 2004, Rochlitz, et al., 2003).  
For example, VACV has been engineered to express prostate-specific antigen (PSA), 
which is over expressed in prostate cancers.  This VACV has proven to induce PSA-
specific T cell responces and therapeutic activity.  In clinical trial the therapy was 
tolerated well and in 78.1% of patients the cancer did not progress (Kaufman, et al., 
2004).   
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1.3.  ADVERSE EVENTS ASSOCIATED WITH THE SMALLPOX VACCINE 
Although VACV is an excellent viral vector, the adverse events associated with 
its use as the smallpox vaccine have constrained it from being more widely utilized as 
vaccines and therapies.  Adverse events associated with the smallpox vaccine fall into 
three major categories according to their severity.  Mild to moderate adverse events 
include feeling sick enough to miss work, fever, and mild rash that resolves without 
intervention.  Moderate to severe adverse events include autoinoculation, generalized 
vaccinia (a rash that covers the entire body but resolves without intervention), and 
myopericarditis.  Severe to life-threatening adverse events include eczema vaccinatum (a 
severe rash on an individual with atopic dermatitis), post-vaccinial encephalitis, and 
progressive vaccinia (vaccinia necrosum) which leads to skin and tissue destruction due 
to uncontrolled replication of the virus in immunocompromised individuals (Fulginiti, et 
al., 2003).  A study of smallpox vaccine complications in 1968 surveyed 10 US states for 
complications.  This study found 529.2 cases of accidental implantation per million, 
241.5 of generalized vaccinia, 12.3 of post-vaccinial encephalitis, and 1.5 of vaccinia 
necrosum (Lane, et al., 1970).  Despite these complications, vaccination efforts during 
the global eradication program led the WHO to declare smallpox eradicated in 1979, 
more than 30 years ago.   
 
1.4.  TREATMENT OF ADVERSE EVENTS 
With the current smallpox vaccine, if adverse events occur, vaccinia 
immunoglobulin (VIG) and investigative new drugs such as cidofovir are approved to 
manage the complications.  Although there is evidence from the smallpox eradication 
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period that suggests individuals with adverse events benefit from VIG treatment, there 
have been no controlled studies.  Intravenous VIG (IGIV produced by Cangene and 
VIGIV produced by Dynport) was licensed by the Food and Drug Administration (FDA) 
for use in 2005 for the treatment of progressive vaccinia, eczema vaccinatum, severe 
generalized vaccinia and extensive body surface involvement or periocular implantation 
(Wittek, 2006).  Side effects associated with VIG treatment, although typically mild, can 
include severe events such as hypotension, renal dysfunction and aseptic meningitis 
syndrome (Cono, et al., 2003). Cidofovir is only recommended to treat adverse events if 
VIG treatment fails or if the patient is close to death.  Side effects associated with 
Cidofovir include renal toxicity, neutropenia, and metabolic acidosis.  Animal studies 
have also shown cidofovir to be carcinogenic (Cono, et al., 2003).   
 
1.5.  CONTRAINDICATIONS FOR SMALLPOX VACCINATION 
As smallpox is no longer present in the world as a natural infection, there are 
many contraindications for receiving the vaccine.  These include current or past history of 
eczema, acute or chronic dermatitis, being immunocompromised or immunosuppressed 
(due to illness, cancer therapy, immunosuppressive treatment after transplantation, or 
HIV/AIDS), heart conditions, pregnancy, or having contacts with anyone who has a 
contraindication (Fulginiti, et al., 2003).  The population at risk for developing adverse 
events has risen since the time of the smallpox eradication program.  With medical 
advances in transplantation, cancer and HIV treatment there are now more people living 
with compromised immune systems, a major contraindication for smallpox vaccination.  
The number of people living with HIV has continued to increase as HIV treatments 
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extend life and as new infections continue to occur each year.  The number of people 
living with HIV worldwide at the end of 2008 was estimated at 33.4 million 
(UNAIDS/WHO, 2009).  The prevalence of eczema has also increased since the smallpox 
eradication era, being estimated to be as high as 20% in Europe, Australia, and the United 
States (Brown and Reynolds, 2006).  It has been estimated that 25% of the United States 
population is contraindicated for smallpox vaccination (Kemper, et al., 2002).  The 
increasing number of people with major contraindications would greatly complicate 
smallpox vaccination efforts with the standard smallpox vaccine if it needed to resume, 
and it hampers the widespread use of VACV as a vaccine and therapeutic vector.   
 
1.6. CURRENT STATUS OF SMALLPOX VACCINATION IN THE UNITED 
STATES 
Although smallpox is no longer a naturally occurring infection, there is still the 
threat of reemergence through a bioterrorist event.  Due to that threat, military personal, 
first responders, and researchers working with orthopoxvirues are still vaccinated against 
smallpox using VACV.  However, the vaccine is not available to the general public since 
it would provide little benefit and may actually cause harm (Bozzette, et al., 2003).  The 
United States military vaccine program has shown that careful screening and education of 
the vaccine recipient lowers the occurrence of adverse events below the historical rates 
from the eradication program era (Grabenstein and Winkenwerder, 2003).  If smallpox 
were to reemerge through a bioterrorism event, or if another orthopoxvirus emerged as a 
significant human pathogen (e.g., monkeypox), mass vaccination with VACV may need 
to resume either in isolated populations or entire geographical regions. Current guidelines 
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state that in an emergency situation (for example the intentional release of the smallpox 
virus), no absolute contraindications would exist for persons exposed to smallpox 
(Centers for Disease Control and Prevention, 2001).  Contraindications would be 
disregarded in this setting because individuals that are at the greatest risk for serious 
adverse events are also at the most risk for death from smallpox (Centers for Disease 
Control and Prevention, 2001). 
 
1.7.  NEW GENERATION SMALLPOX VACCINES 
As safety is the foremost priority for a vaccine, there is a need to develop safer, 
new generation vaccines for smallpox.  While the focus of new smallpox vaccines is on 
improved safety, their efficacy must also be maintained or improved.  Dryvax is a first-
generation vaccine that was used during the United States eradication campaign of the 
1970s.  It is based on the New York City Board of Health (NYCBH) strain of VACV and 
was produced by Wyeth Laboratories (Handley, et al., 2009).  This vaccine was 
propagated in the skin of calves and isolated by skin scraping (Artenstein, 2008).  
ACAM2000 recently replaced Dryvax as an improved second-generation vaccine.  This 
vaccine was licensed for use in the United States in 2007, and is clonally derived from 
the Dryvax vaccine by plaque purification.  ACAM2000 is propagated in tissue culture, 
decreasing the risk of contamination by microbial agents.  It is also less neurovirulent 
than the Dryvax vaccine (Monath, et al., 2004).  ACAM2000 was able to be licensed 
because it demonstrated equivalent immunogenicity to the Dryvax vaccine, which is a 
requirement for new smallpox vaccines (Artenstein, 2008).  Vaccination with either 
Dryvax or ACAM2000 by scarification produces a scar, known as the vaccine “take”.  
  8 
There is a direct relationship between the take and protection from smallpox (Artenstein, 
2008), and the take is generally considered the only known correlate of protection for 
smallpox. 
New generation smallpox vaccines all focus on increasing vaccine safety while 
maintaining efficacy.  Many new generation vaccines have taken the approach of 
attenuating the vaccine virus.  Such vaccines include MVA (modified vaccinia Ankara) 
and NYVAC.  NYVAC was developed by deleting 18 VACV genes, leaving the virus 
unable to replicate in humans (Tartaglia, et al., 1992).  MVA was generated by passing 
VACV in chick embryo fibroblasts (>570 times) until the virus lost the ability to replicate 
in most mammalian cells.  This virus has been studied extensively as a safer alternative to 
replication competent VACV.  As MVA cannot replicate in human cells, no serious 
adverse events have been associated with its use in humans.  Although MVA was used 
during the eradication period, it was never utilized in an area where smallpox was 
endemic, and therefore the efficacy of MVA against variola has never been assessed.  
While MVA is undisputedly safer than replication competent smallpox vaccines, it has 
been shown to require multiple doses to achieve immunogenicity equivalent to Dryvax 
(Grandpre, et al., 2009, Parrino, et al., 2007, Wyatt, et al., 2004).   
Unfortunately the use of a replication deficient smallpox vaccine requiring a 
multi-dose regimen is unfeasible in the event of a bioterrorist event involving smallpox.  
One suggested approach for the use of MVA or other replication deficient VACVs is to 
immunize before there is any risk of smallpox infection and boost with the standard 
smallpox vaccine or with MVA in the event of an immediate threat (Earl, et al., 2004).  
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This proposed vaccination scheme would require keeping the population vaccinated with 
MVA in preparation for a possible smallpox threat.     
Even with the improvements provided by ACAM2000, there is still an urgent 
need to develop an even safer smallpox vaccine for the ever-increasing population with 
contraindications that at a minimum retains the ability to elicit the protective immunity 
that the first-generation vaccines provided.   
 
1.8.  HYPOTHESIS 
The goal of increasing vaccine safety while maintaining efficacy has proven to be 
difficult.  The approach of attenuating VACV, while successful at minimizing adverse 
events, has come at the cost of efficacy and the uncertainty of its ability to provide 
protection equivalent to first-generation vaccines.  In an effort to maintain vaccine 
efficacy while increasing safety, I hypothesize that elements of the tet operon can be used 
to control the transcription of a VACV gene essential for virus growth, thereby regulating 
replication of the virus.  These viruses would address the need for a safer, yet 
indisputably protective, smallpox vaccine.   
Regulation of an essential gene can be achieved by constitutively expressing the 
TetR repressor protein within the VACV genome and incorporating a tet operator (tetO) 
into the promoter of an essential gene (Figure 1-1). 
 
  
Figure 1-1.  Tetracycline 
of tetracycline (denoted by yellow star)
operator sequence in the promoter for the essential 
In the presence of tetracyclines, tetracycline binds TetR and prevents TetR from 
interacting with the operator, thus allowing transcription of the essential gene. 
 
1.9.  SIGNIFICANCE OF PROPOSED WORK
The inducible VACVs generated will have many potential uses.  The new 
recombinant VACVs could serve as 
as efficacious as ACAM2000.  They could also act as new generation viral vectors for 
both human and animal vaccines, and as
for the recipients of the vaccine or therapy, but also 
vectors (e.g., vaccinators) and contacts of the vaccine/therapy recipients.
The inducible VAC
vaccine.  As the inducible viruses can be made utilizing the ACAM2000 vaccine strain or 
another first-generation vaccine strain, the immune response that will be generated by the 
inducible VACVs should be 
10 
Induced Gene Expression in Vaccinia Virus
 TetR protein is produced and binds to the 
VACV gene, preventing transcription.
 
new generation smallpox vaccines that are 
 oncolytic vectors.  They would be safer
for the personnel administering the 
 
Vs are excellent candidates for a new generation smallpox 
extremely similar (if not identical) to the current vaccine
 
.  In the absence 
 
 
safer and 
 not only 
 and 
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produce a “take”.  These similarities would allow the vaccine to fulfill the non-inferiority 
to ACAM2000 requirement for FDA licensure.  If utilized as the smallpox vaccines, the 
inducible VACVs could be administered to individuals whom have contacts with 
contraindications.  This would prevent the vaccinee from transmitting the virus to 
contacts (as long as the contacts were not receiving tetracycline treatment).  
This inducible form of vaccination would have been particularly useful in a case 
of inadvertent inoculation that occurred in Indiana in 2007.  A United States service 
member received smallpox vaccination in preparation for deployment, when his 
deployment was delayed he made an unplanned visit to his family.  His son, who had 
eczema, developed a life-threatening case of eczema vaccinatum which required 
investigational antivirals (cidofovir), VIGIV, and 48 days of hospitalization to recover 
(Centers for Disease Control and Prevention, 2007).  If the inducible VACV had been 
used, inadvertent inoculation could have been avoided, as tetracyclines would need to be 
taken with the vaccine for viral replication to occur.  As long as the child was not taking 
tetracyclines the virus would not have been able to replicate and eczema vaccinatum 
would not have developed.  Since VACV is also used in cancer immunotherapy and as an 
oncolytic vector in patients that can be mildly to severely immunocompromised, use of 
inducible VACV vectors would greatly enhance the safety of these therapies. 
 
1.10.  INDUCIBLE VACCINIA VIRUS SYSTEMS 
Two operon systems have been adapted for use in VACV, the lac operon system 
and more recently the tet operon system.  The lac operon system was first adapted to 
VACV in 1989, when it was used to regulate the expression of an inserted β-
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galactosidase gene.  The lac repressor (lacI) was inserted into the VACV genome under a 
constitutive promoter and the lac operator (lacO) was inserted after a strong VACV late 
promoter initiator sequence prior to the translational start site of the β-galactosidase gene.  
This genetic setup made the expression of β-galactosidase dependent on the inducer 
IPTG (isopropyl-β-D-thiogalactoside) (Fuerst, et al., 1989).   This same lac operon setup 
was later used to control the expression of the VACV p11 (F17R) gene (Zhang and Moss, 
1991a).  The ability to control gene expression through the addition of inducer is a 
powerful method to investigate the function of individual VACV genes.  The lac operon 
has been utilized to investigate the function of numerous VACV genes, including p11, 
early transcription factors, RNA polymerase associated protein, and membrane proteins. 
The most common genetic setup using the lac operon involves the use of the 
bacteriophage T7 RNA polymerase and is commonly referred to as vIT7LacO.  For this 
genetic arrangement, elements are typically inserted into the TK (or another nonessential) 
region of the virus.  The P7.5 promoter expresses the lacI gene constitutively and the 
inserted bacteriophage T7 RNA polymerase gene is under the control of a strong late 
promoter (e.g, P11) with a lac operator sequence inserted between the start site of the gene 
and the initiator of the promoter.  This causes the expression of the T7 RNA polymerase 
to be inducible by IPTG.  To regulate the gene of interest (originally tested with the β-
galactosidase gene), it was placed under the control of a T7 promoter (sometime also 
incorporating a lacO sequence), making the expression of β-galactosidase inducible by 
IPTG (Alexander, et al., 1992).  More recently the tet operon system has been adapted to 
VACV.  The tet operon was first used in VACV as an alternative to the lac operon 
system to regulate the expression of the A14L gene (Traktman, et al., 2000).   
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1.11.  THE TETRACYCLINE OPERON 
In an effort to improve the safety of VACV vectors while maintaining efficacy, 
elements of the tet operon will be used to control the transcription of VACV genes 
essential for virus growth, thereby regulating replication of the virus.  The tet operon is 
carried on transposon 10 in E. coli, conferring resistance to tetracyclines.  It consists of 
two genes, the resistance gene (tetA) and the repressor gene (tetR) (Postle, et al., 1984).  
The tetR gene produces a repressor protein (TetR) that binds to the tet operator sequences 
(tetO) that overlap tet operon promoters, thus inhibiting the transcription of the tet operon 
genes.  TetR binds to tetracyclines (e.g., tetracycline, doxycycline, and 
anhydrotetracycline), altering its conformation so that it is unable to bind to the operator 
sequences, thus allowing transcription of the operon genes (Hillen and Berens, 1994).  
The two binding sites (operators) for TetR in the tet operon (O1 and O2) consist of 19 bp 
sequences that bind two homodimeric molecules of TetR as a dimer.  Even though O1 is a 
perfect palindrome around a T/A center of symmetry and O2 is an imperfect palindrome, 
TetR binds to operator O2 with three- to five-fold higher affinity than to operator O1 
(Hillen and Berens, 1994). 
The tet operon has been adapted to VACV where it was used to investigate the 
function of A14, a membrane protein, during VACV life cycle.  The O2 sequence was 
inserted between the transcriptional and translational start sites of the A14L gene, and 
tetracycline was able to regulate the expression of the A14L gene (Traktman, et al., 
2000).  More recently, the expression of reporter genes and cytokines both in vitro and in 
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vivo were controlled using several different promoters and operator sequence 
combinations (P. Oliveira-Weber et al., unpublished data; Weber, et al., 2007). 
 
1.12.  TETRACYCLINES  
Tetracyclines, a group of antibacterials first used in the 1950s, includes 
tetracycline, doxycycline, minocycline, and numerous others.  Tetracycline antibiotic 
activity results from the molecule binding to ribosomes, causing the inhibition of 
bacterial protein synthesis.  Tetracycline (a group 1 tetracycline) was introduced in 1950 
and is less lipophilic than group 2 tetracyclines, which includes doxycycline.  
Tetracycline is absorbed at 77-88% and the peak concentration in the serum (1-5 mg/l), is 
reached between 2-4 h when a 250-500 mg dose is given.  The serum half-life of 
tetracyclines is 6-10 h.  Doxycycline is thought to be almost completely absorbed when 
taken orally, reaches peak concentrations by 2-3 h, and has a long half-life of 
approximately 20 h (Agwuh and MacGowan, 2006).  The typical tetracycline dose for 
adults is 500 mg twice daily.  Complications associated with treatment using tetracyclines 
are generally mild and can include: photosensitivity (not typically associated with 
doxycycline or minocycline), discoloration to teeth (infancy to the age of 8), nausea, and 
diarrhea.  Treatment with tetracyclines is not indicated for pregnant women and children 
less than 8 years of age (Cunha, 2001).  Tetracycline treatment is generally safe and is 
utilized to treat many infections (Table 1-1).  
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Table 1-1:  Uses and Doses of Different Tetracyclines. 
Antibiotic Treatment Dose Duration Reference 
Doxycyline Adult Early 
Lyme Disease 
100 mg, twice daily 14-21 
days 
(Wormser, et al., 
2000) 
Doxycycline Lyme Disease in 
Children >8 yrs 
1-2 mg/kg, twice 
daily (max. dose 500 
mg) 
14-21 
days 
(Wormser, et al., 
2000) 
Doxycycline Moderate Acne 20-100 mg, twice 
daily 
- 
(Haider and Shaw, 
2004) 
Tetracycline Moderate Acne 500 mg, twice daily - (Haider and Shaw, 
2004) 
Tetracycline Cholera 200-400 mg, daily 3-5 days (Wallace, et al., 
1968) 
 
1.13. VACCINIA VIRUS REPLICATION 
Unlike most DNA viruses, poxviruses are unique in that they replicate in the cell 
cytoplasm, instead of the nucleus.  Replication can occur in the cytoplasm because the 
virus encodes all proteins necessary for its replication, such as DNA and RNA 
polymerases (Moss, 2007).  Transcription of VACV genes occurs in three stages: early, 
intermediate, and late.  During each stage, proteins that allow transcription to progress to 
the next stage (e.g., transcription factors) are produced.  VACV promoters determine the 
stage at which each gene will be transcribed.  After VACV attaches to a cell, it releases 
its core into the cytoplasm.  The core contains all of the factors necessary for early 
transcription; this allows early mRNA to be synthesized and early proteins to be 
expressed.  After early transcription, uncoating occurs and the viral DNA is replicated 
within viral factories (granular foci within the cell that do not contain normal cellular 
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organelles).  Intermediate transcription then takes place using the replicated DNA as a 
template.  This is followed by late transcription, which produces abundant amounts of 
structural proteins, as well as all of the proteins required for early transcription.  Virion 
morphogenesis follows, in which these proteins and the replicated DNA are packaged 
into new virions.  Virion morphogenesis is first evidenced by the appearance of crescent-
shaped membrane structures; these crescents turn into immature virions (IV), which may 
contain nucleoids of electron-dense DNA (INV, immature virion with nucleoid).  The IVs 
continue to mature into infectious particles, either intracellular mature virions (IMVs) or 
extracellular enveloped virions (EEVs).  The majority of the virus particles remain as 
IMVs within the cell and are thought to mediate spread between hosts, while EEVs are 
released from the cell by budding and are responsible for dissemination of the virus 
within the host (Moss, 2007).   
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CHAPTER 2:  USE OF VACCINIA VIRUS EARLY D1R GENE TO 
CONTROL VIRAL REPLICATION 
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2.1.  INTRODUCTION 
To control the replication of VACV with tetracyclines, the VACV D1R gene was 
chosen to be placed under the control of tet operon elements.  A comprehensive 
investigation of VACV genes directly involved in virus replication led to this decision.  
Candidate genes were selected based on their presumed function in the virus life cycle 
(e.g., RNA and DNA polymerases, transcription factors, etc.) and on published 
experimental work.  A total of 16 essential candidate genes were initially identified.  The 
positions of these genes in the VACV genome and their upstream intergenic regions (the 
region between the start site of the essential gene candidate and the end or start of the 
upstream gene) were then carefully inspected to determine if it would be possible to 
insert the tet operon elements without disrupting transcription of the surrounding genes.  
For example, the early transcription factor large subunit (A7L) was not considered an 
ideal essential gene candidate because its intergenic region contains both the promoter for 
the transcription factor and a promoter for the upstream gene.  Likewise, the promoter for 
the RNA polymerase 22 kDa subunit gene (J4R) is located within the upstream gene.  
Inserting tet operon elements before either gene would cause the transcription of both the 
essential gene and the upstream gene to be affected.  This initial analysis narrowed the 
number of candidate genes to seven. 
All candidate essential genes with appropriate intergenic regions were then further 
researched to determine if they would be able to control VACV replication.  B1R (a Ser-
Thr kinase), E8R (a membrane protein) and D1R (the large subunit of the capping 
enzyme) were the three best essential candidate genes.  Studies of E8R demonstrated only 
a reduction in plaques formed by temperature sensitive- (ts) mutants and studies of B1R 
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were only able to show that attempts to delete the gene were unsuccessful, suggesting 
that the gene is essential to viral replication (Kato, et al., 2007, Rempel and Traktman, 
1992).  A study of the D1R gene done by Shatzer et al. showed that ts-mutants were 
unable to generate any infectious progeny at non-permissive temperatures, indicating that 
the gene is essential for viral replication (Shatzer, et al., 2008).  The D1R gene is 
expressed early (Lee-Chen, et al., 1988) and has been shown to have multiple roles in the 
VACV replication cycle.  It functions not only as a capping enzyme, but also has roles in 
early gene transcription termination and in intermediate gene transcription initiation 
(Harris, et al., 1993, Hassett, et al., 1997, Shatzer, et al., 2008).  After careful 
consideration, the D1R gene was chosen as the ideal essential gene because it was shown 
to be required for VACV replication and it is expressed under an early promoter (its 
repression should be able to stop replication of VACV at an early stage of the virus life 
cycle).   
To utilize the D1R gene to generate an inducible recombinant VACV that 
replicates only in the presence of tetracyclines, tetO sequences were incorporated into the 
promoter for the D1R gene and by inserting the tetR gene (under a constitutive promoter) 
into the VACV genome.  The resulting recombinant VACV (viD1R) was expected to be 
able to replicate only in the presence of tetracyclines.   
Two recombinant VACVs were be designed: 1) viD1R (for VACV Inducible 
D1R) expressing TetR constitutively and having the D1R gene under the control of a tet-
responsive early synthetic promoter (PiSE).  The replication of this virus was expected to 
occur only in the presence of tetracyclines.  2) viD1Rc (for VACV Inducible D1R 
control) also expressing TetR constitutively but having the D1R gene under the control of 
  20 
its natural promoter (PD1R).  This virus was expected to replicate both in the presence and 
absence of tetracyclines.   
The strategy aims to control the replication of VACV by inducing the essential 
gene through the addition of tetracyclines (e.g., doxycycline).  This control over viral 
replication will increase the safety of VACV as a vaccine vector.  If adverse events arise 
after vaccination with the recombinant VACV, the removal of doxycycline will stop or 
greatly attenuate the replication of the virus, giving the innate and adaptive immune 
systems the opportunity to clear the virus, stopping the adverse event.   
 
2.2.  MATERIALS AND METHODS 
 
2.2.a.  Research Design: 
An inducible recombinant VACV was designed by incorporating tetO sequences into 
the promoter for the VACV D1R essential gene and inserting the tetR gene (under a 
constitutive promoter) into the D1R-H7R intergenic region of the VACV genome.  The 
resulting recombinant VACV (viD1R) is expected to be able to replicate only in the 
presence of tetracyclines.   
 
Recombinant viruses designed: 
1. viD1R (for VACV Inducible D1R) expressing TetR constitutively and 
having the D1R gene under the control of a tet-responsive early synthetic 
promoter (PiSE) -- replication of this recombinant should only occur in the 
presence of tetracyclines.  
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2. viD1Rc (for VACV Inducible D1R control) also expressing TetR 
constitutively but having the D1R gene under the control of its natural 
promoter (PD1R) -- replication of this recombinant should occur both in the 
presence and absence of tetracyclines. 
 
2.2.b.  Early Tet-Responsive Promoter Design for viD1R: 
Typical poxvirus promoters are about 30 bp in length with a core, spacer, and 
initiator regions (Moss, 2007).  Early VACV promoters have a fairly conserved core 
region followed by an 11-16 bp spacer and a single purine initiator sequence (Broyles, 
2003, Chakrabarti, et al., 1997, Davison and Moss, 1989, Moss, 2007).  Extensive 
analysis of the early core sequences performed in the Verardi Laboratory suggested that 
the sequence, AAAAATAGAAACCATA, would serve as an optimal early core region 
(J. Sopronyi et al., unpublished data).  To generate an early tet-responsive promoter for 
the D1R gene, the 19-bp tet operator sequence O2 (TCCCTATCAGTGATAGAGA) was 
inserted between this designed core region and the translational start site of the D1R gene 
to originate the synthetic early promoter PiSE (AAAAATAGAAACCATATCCCTATC-
AGTGATAGAGA).  This new synthetic promoter would be expected to have the lowest 
levels of expression under repressible conditions, since the putative purine initiator 
sequences (underlined) are part of the operator sequence (in bold) (Table 2-1).   
 
2.2.c.  Natural D1R Promoter Sequence for viD1Rc: 
To generate an appropriate control virus expressing D1R constitutively, the 
intergenic sequence between the D1R and the upstream H7R gene coding sequences, plus 
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the last 9 bp from the H7R gene coding sequence, were used to design the natural D1R 
promoter sequence (PD1R, GCTTGTTAATAAGTAAATGAAAAAAAACTAGTCGTT-
TATAATAAAACACGAT).  H7R, the gene upstream from D1R, has a role in the 
formation of crescent membrane precursors and immature virions (Satheshkumar, et al., 
2009).  Since the D1R promoter has not been mapped, the 9 bp from the end of the H7R 
gene (in bold) were incorporated to ensure that the full natural D1R promoter is present 
(Table 2-1).  In particular, any potential G nucleotides (required by early promoters 
around position -21) were included in the sequence (Broyles, 2003, Chakrabarti, et al., 
1997, Davison and Moss, 1989, Moss, 2007).  
 
Table 2-1:  Recombinant Vaccinia Viruses and their Respective D1R Promoter 
Sequences. 
Recombinant 
Vaccinia 
Virus 
Inducible 
Promoter 
Name 
 
Promoter Sequencea 
viD1R PiSE AAAAATAGAAACCATATCCCTATCAGTGATAGAGA 
viD1Rc PD1R GCTTGTTAATAAGTAAATGAAAAAAAACTAGTCGTTTAT-
AATAAAACACGAT 
a
 In the PiSE promoter the tetO2 sequence is in bold and underlined are potential early 
initiators of transcription.  In the PD1R promoter the last 9 bp of the upstream H7R gene 
are in bold. 
 
2.2.d.  Construction of Transfer Vectors for viD1R and viD1Rc: 
 A series of cloning steps was used to build the transfer vectors to generate the 
recombinant VACVs, based on existing plasmids and designed synthetic DNA 
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sequences.  The final transfer vectors contain: (1) the selectable E. coli xanthine-guanine 
phosphoribosyl transferase (gpt) gene and the screening marker β-glucuronidase (gusA) 
gene, as a fusion gene (gpt-gus) under control of the synthetic early/late promoter Psel 
(Hammond, et al., 1997); (2) a second screening marker, the DsRed-Express gene 
(DsRed) encoding a red fluorescent protein under control of the natural late P11 promoter; 
(3) the repressor gene tetR under the synthetic early/late promoter PE/L (Chakrabarti, et 
al., 1997); and (4) either the PiSE or PD1R promoter to direct the expression of the D1R 
gene.   
 All of these elements were placed between the left border (LB) (the last 524 bp of 
the H7R gene, upstream of D1R) and right border (RB) (the first 600 bp of the D1R 
gene), which serve as recombination sequences for homologous recombination.  Briefly, 
the EcoRI-BglII fragment (containing gtp-gus and DsRed genes) from pSMART10 
(Weber, et al., 2007) was cloned into the EcoRI-BclI site of pCH001 (a synthetic plasmid 
containing the left and right recombination sequences for assembly of the final transfer 
vectors obtained from DNA2.0 (Menlo Park, CA), originating pCH003.  Next the SphI-
XmaI fragment of pSMART10 (containing tetR) was cloned into the same sites of 
plasmid pCH003, resulting in the final transfer vector (pCH004), which was used to 
generate viD1R (Figure 2-1).  To generate the final transfer vector for viD1Rc, the SphI-
XhoI fragment of plasmid pCH004 (containing PiSE and the Right Border) was replaced 
with the SphI-XhoI fragment of the synthetic plasmid pCH002 (containing PD1R and the 
Right Border, DNA2.0), generating plasmid pCH005 (Figure 2-1).   
 
 
  
 
Figure 2-1.  Construction of F
cloning steps used to generate the final transfer vectors are depicted
express the gpt-gus, DsRed, and 
vector pCH004 was designed to express the 
PiSE promoter, while pCH005 expresses the 
(PD1R).  All of these genetic elements for both plasmids are 
(H7R LB) and Right Border (D1R RB) sequences, which direct homologous 
recombination with the VACV genome to generate viD1R and vi
 
2.2.e.  Generation of Recombinant Viruses:
Homologous recombination was used to precisely insert th
between the left and right b
region between the essential and 
of the essential gene.  This step replaced the natural D1R
24 
inal Transfer Vectors pCH004 and pCH005.
.  Both vectors 
tetR genes under constitutive promoters.  The transfer 
D1R gene under the synthetic inducible early 
D1R gene under its natural early promoter 
flanked by the Left Border 
D1Rc. 
 
e genetic elements 
orders of each of the final transfer vectors into the intergenic 
upstream genes, placing the inducible promoter in front 
-H7R intergenic region (43 bp) 
 
  The 
  25 
with the desired genetic elements (for viD1R 3865 bp were inserted; for viD1Rc 3871 bp 
were inserted).  The recombinant VACVs were generated by standard homologous 
recombination via transfection of the transfer vectors pCH004 and pCH005 into BS-C-1 
cell monolayers infected 2 h earlier at 0.05 PFU per cell with VACV strain Western 
Reserve (WR) clone 9.2.4.8 (obtained from T. Yilma, University of California Davis).  
Recombinant gpt-positive VACVs were plaque purified on BS-C-1 cells from 
transfection lysates using gpt selection medium (25 µg/ml mycophenolic acid, 250 µg/ml 
xanthine, and 15 µg/ml hypoxanthine) (Legrand, et al., 2004).  All recombinants were 
plaque-purified in the presence of inducer (1 µg/ml doxycyline).  Expression of DsRed 
was detected via fluorescence microscopy (Carl Zeiss Axio Observer D1) to ensure that 
the recombinant viruses were free of parental virus.  
 
2.3.  RESULTS 
 During plaque purification of the recombinant viruses it was observed that many 
of the recombinant plaques that grew in gpt selective media were not expressing DsRed, 
but were expressing the gus gene indicating that the recombinants (both viD1R and 
viD1Rc) do not contain all of the inserted genetic elements (Figure 2-2).  It was also 
observed that doxycycline had no effect on the replication of viD1R, the virus replicated 
both in the presence and absence of doxycycline.   
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CHAPTER 3:  IMPROVEMENT OF TRANSFER VECTORS 
 
  
3.1.  INTRODUCTION 
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3.2.  MATERIALS AND METHODS 
 
3.2.a.  Re-design of Transfer Vectors for viD1R and viD1Rc: 
A new gpt-EGFP fusion gene was generated.  A synthetic plasmid containing the 
EGFP sequence with an NcoI site at the 5’ end and an AatII-EcoRI site at the 3’ end 
(pCH035) was used to generate the gpt-EGFP fusion gene. The synthetic EGFP gene 
was cloned into the pSMART10 plasmid (replacing the GUS gene) to generate pCH030 
containing the gpt-EGFP fusion gene.  The fusion gene was sequenced to confirm the 
sequence of gpt-EGFP.   
A series of cloning steps was then used to build the transfer vectors to generate 
the recombinant VACVs (viD1R2 and viD1Rc2), based on existing plasmids and designed 
synthetic DNA sequences.  The final transfer vectors contain: (1) the selectable E. coli 
xanthine-guanine phosphoribosyl transferase (gpt) gene and the screening marker EGFP 
gene, as a fusion gene (gpt-EGFP) under control of the synthetic early/late promoter PE/L; 
(2) the repressor gene tetR under PE/L promoter (Chakrabarti, et al., 1997); and (4) either 
the PiSE or PD1R promoter to direct the expression of the D1R gene.   
All of these elements were placed between the left border (the last 524 bp of the 
H7R gene, upstream of D1R) and right border (the first 600 bp of the D1R gene), which 
serve as recombination sequences for homologous recombination.  Briefly, the EcoRI-
SphI fragment (containing back-to-back PE/L promoters) from pCH029 (from DNA2.0) 
was cloned into the EcoRI-SphI site of pCH001 (a synthetic plasmid containing the left 
and right recombination sequences for assembly of the final transfer vectors obtained 
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from DNA2.0), originating pCH031.  Next the XmaI-NheI fragment of pCH004 
(containing tetR) was cloned into the same sites of plasmid pCH031, resulting in 
pCH032.  Finally the SacI/AatII fragment from pCH030 (containing the gpt-EGFP gene) 
was inserted into the same site of pCH032 generating the final transfer vector pCH033, 
which was used to generate viD1R2 (Figure 3-2).  To generate the final transfer vector for 
viD1Rc2, the SphI-XhoI fragment of plasmid pCH0033 (containing PiSE and the Right 
Border) was replaced with the SphI-XhoI fragment of the synthetic plasmid pCH002 
(containing PD1R and the Right Border, DNA2.0), generating final transfer vector 
pCH034 (Figure 3-2).   
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3.2.b.  Generation of Recombinant Viruses: 
Recombinant viruses were generated using the method previously described in 
Chapter 2, section 2.2.e.   
 
3.3.  RESULTS 
Upon plaque purification, no recombination was observed in the recombinant 
VACVs, since all genetic screening/selective genetic elements appeared to be expressed. 
The recombinant viruses were able to grow in MPA selective media and to express EGFP 
(indicating that the viruses were gpt+ and EGFP+), and contained the tetR gene as 
determined by PCR (data not shown).  The current genetic setup appears to prevent 
recombination from occurring among the transfer vector elements.  Upon testing with 
doxycycline there was no observable effect on the replication of either viD1R2 or 
viD1Rc2.  Plaques of similar size were formed both in the presence and in the absence of 
doxycycline, indicating that viral replication is not inducible (Figure 3-3). 
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gene product (small subunit of the capping enzyme) is an enzyme and may not be 
required in high amounts, thus a low level of early transcription may produce a sufficient 
amount for viral replication.  Secondly, as the structure of early promoters is not well 
understood, the operator sequence may not have been inserted in an ideal location 
causing the binding of TetR to be insufficient to prevent transcription of D1R.  
To date, no early gene has ever been successfully controlled by an operon system 
while maintaining its early expression.  Limited success has been achieved by changing 
the stage at which the early gene of interest is transcribed, as was done with the L2R 
gene.  The L2R gene is expressed early in infection, but in an attempt to study its function 
using the lac operon, the promoter of the gene was changed to a T7 RNA polymerase 
promoter.  Utilizing a genetic arrangement, in which the T7 RNA polymerase is under the 
control of a late promoter containing a lacO sequence, the transcription of L2R was 
successfully regulated by IPTG.  Although gene expression was successfully regulated, a 
delay in virus replication of several hours was observed possibly due to the change in the 
time of expression of L2R (Maruri-Avidal, et al., 2011).   
Due to the inherent difficulties in regulating early transcription using operon 
systems as observed in this system and by others as well, late VACV genes may be better 
candidates for the inducible control of VACV replication. 
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CHAPTER 4:  USE OF VACCINIA VIRUS LATE GENES TO 
CONTROL VIRAL REPLICATION 
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4.1.  INTRODUCTION 
Controlling early gene expression through the use of operon systems has proven 
to be very challenging; controlling late gene expression may be a better alternative to 
generate inducible VACV recombinants.  Several inducible VACVs were designed by 
placing late genes essential for VACV replication under the control of tet operon 
elements, allowing viral replication to occur only in the presence of tetracyclines.  These 
inducible recombinant VACVs were designed by incorporating tetO sequences into the 
promoters for selected essential late genes (A3L, A6L, A7L, D6R, E8R, and F17R) and 
inserting the tetR gene (under a constitutive promoter) into the VACV genome.  The 
resulting recombinant VACVs were expected to only be able to replicate in the presence 
of tetracyclines.   
The late essential genes were selected based on their presumed function in the 
virus life cycle (e.g., RNA and DNA polymerases, transcription factors, etc.) and on 
published experimental work.  A total of 27 late essential candidate genes were initially 
identified.  The promoters of each gene were then investigated to determine if a 
characteristic late transcription initiator (TAAAT) was present and the positions of these 
genes in the VACV genome and their upstream intergenic regions (the region between 
the start site of the essential gene candidate and the upstream gene) were carefully 
inspected to determine if it would be possible to insert the tet operon elements without 
disrupting transcription of the surrounding genes.  For example, the RNA polymerase 132 
kDa subunit (A24R) is not an ideal essential gene candidate because its promoter is 
located within the upstream gene (A23R). Inserting tet operon elements into this 
intergenic region would cause the transcription of the both the essential gene and the 
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upstream gene to be affected.  Similarly, the E10R gene is not an ideal candidate because 
its promoter is back-to-back with the early promoter for the DNA polymerase gene 
(E9L).  As the exact sequence of the early promoter for E9L could not be accurately 
determined and transcription of E9L would likely be disrupted by inserting the tet operon 
elements into this intergenic region, the E10R gene was not considered an ideal 
candidate.  This analysis further narrowed the list of candidate genes; all remaining genes 
with appropriate intergenic regions were then further researched to determine if they 
would be able to control VACV replication.  Based on this criteria the following late 
essential genes were chosen: A3L (precursor of core protein 4b), A6L (involved in the 
formation of mature virions), A7L (large subunit of the early transcription factor), D6R 
(small subunit of the early transcription factor), E8R (membrane protein), and F17R 
(virion core protein). 
 
4.1.a.  A3L Gene: 
The A3L gene encodes the 72.5 kDa precursor to virion core protein 4b.   
Precursor 4b is proteolytically processed by the I7L gene product into 4b, a 60 kDa core 
protein.  Core protein 4b accounts for 11% of the virion mass and has been localized to 
the surface of virion cores (Moss and Rosenblum, 1973, Sarov and Joklik, 1972, Wilton, 
et al., 1995).  Temperature sensitive mutants that map to the A3L gene were used to 
investigate the role of A3 in virion morphogenesis.  These mutants had normal patterns of 
gene expression and DNA replication, but were defective in the transition from immature 
virions containing nucleoids (IVN) to intracellular mature virus (IMV) (Kato, et al., 
2004).  Infections at the nonpermissive temperature formed normal IV (immature virions) 
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and IVN, but no normal IMVs were produced.  The particles that were produced were 
abnormal in shape.  The infectivity of these misshapen virions was reduced 30-100 fold 
and showed transcription levels as low as 2% of wild type levels (Kato, et al., 2004).  
Repression of the I7L gene product, which is responsible for cleaving the precursors of 
core protein 4b as well as core proteins 4a and 25k, also causes a defect in virion 
morphogenesis very similar to the A3L temperature sensitive mutants, further suggesting 
that core protein 4b is essential to VACV (Ansarah-Sobrinho and Moss, 2004, Byrd and 
Hruby, 2005, Kane and Shuman, 1993).  An inducible A3L VACV mutant has not yet 
been generated.  
 
4.1.b.  A6L Gene: 
VACV gene A6L is one of 91 open reading frames (ORFs) conserved among all 
chordopoxviruses (Upton, et al., 2003).  A6 has been shown to be a minor virion 
component in VACV via mass spectrometry (Chung, et al., 2006).  The A6 homolog of 
myxoma virus has also been identified as part of the virion core (Zachertowska, et al., 
2006).  Temperature sensitive mutants and a recombinant VACV encoding A6L with an 
epitope tag have been used to characterize the function of the A6L gene in the VACV 
lifecycle.  The A6L gene product is expressed late in infection, tightly packaged into the 
virion core and appears to be essential in virion morphogenesis (Meng, et al., 2007).  At 
the non-permissive temperature, ts-mutants were unable to produce infectious progeny 
and could not process the precursors of major virion proteins 4a and 4b (Meng, et al., 
2007).  At the non-permissive temperature, virion morphogenesis of the ts-mutants was 
blocked at the IV stage prior to IVN.  Several proteins co-precipitate with A6 leading to 
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speculation that A6 may help with assembly of the virion core through its interaction with 
other viral proteins.  An inducible recombinant for the A6L gene has not yet been 
successfully constructed.  Lac operon inducible recombinants for the A6L gene have been 
attempted, but have not been successfully generated (Meng, et al., 2007).  
 
4.1.c.  A7L and D6R Genes: 
The VACV early transcription factor (VETF) is composed of two subunits (a 
small 70 kDa subunit and a large 82 kDa subunit).  The D6R gene encodes the small 
subunit and the large subunit is encoded by A7L.   The VACV A7L gene is referred to as 
A8L in some literature; currently the A8 ORF is considered to be A8R and to encode a 
subunit of the intermediate transcription factor (Sanz and Moss, 1999).  The VETF 
subunits are produced late in infection and packaged into the virus to be used in the next 
round of replication.  VETF provides early promoter specificity to the RNA polymerase, 
by binding early promoters and recruiting the RNA polymerase for transcription of early 
genes (Baldick, et al., 1994, Li and Broyles, 1993b).  The H4L gene product (RAP94) is 
also required for early gene transcription and is believed to have a role in docking the 
RNA polymerase to the VETF (Ahn, et al., 1994, Broyles, 2003).  A7, the large subunit, 
interacts with the core region of the early promoter while D6, the small subunit, interacts 
with the promoter’s downstream region (Cassetti and Moss, 1996).  The small subunit of 
the VETF also contains the DNA-dependent ATPase activity of the transcription factor 
(Li and Broyles, 1993a).    
An inducible A7L VACV mutant was created using the lac operon system.  The 
T7 RNA polymerase gene, under the VACV late P11 promoter containing a lac operator, 
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was inserted into the VACV genome and the A7L gene was placed under the control of a 
bacteriophage T7 promoter.  This inducible system used IPTG to regulate the production 
of the T7 RNA polymerase and thus the transcription of the A7L gene.  The replication of 
this mutant was shown to be dependent on inducer and the repression of A7 interfered 
with virion morphogenesis.  In the absence of inducer, one-step growth curves showed 
little or no increase in viral titer compared to a 2-log increase in the presence of inducer.  
The repression of A7 produced immature and dense intermediate particles that did not 
have the characteristic brick structure and very few mature particles were produced.  
Only 5.6% of all particles formed were mature virions compared to 33.4% in the presence 
of inducer (Hu, et al., 1998).   
An inducible D6R mutant was also generated using the T7lacO system.  The D6R 
gene was placed under the control of a T7 promoter and the inserted T7 RNA polymerase 
gene was regulated by the VACV late P11 promoter with a lac operator, causing the D6R 
gene to be inducible by IPTG.  Plaque formation of this mutant was dependent on the 
presence of inducer.  Similar to the repression of A7, the repression of D6 also interfered 
with morphogenesis of the virus.  In the absence of inducer, immature virions were found 
next to large granular masses and were round rather than brick shaped, and mature 
virions were not frequently observed (Hu, et al., 1996).   
The disruption of virion morphogenesis caused by the repression of the VETF 
subunits may indicate a direct role for the VETF in virion morphogenesis or VETF may 
be required for the transcription of a unique set of late genes (Hu, et al., 1996, Hu, et al., 
1998).  The possibility of the VETF being required for transcription late in infection 
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supports the transcriptional reactivation of certain early promoters at late times (Garces, 
et al., 1993).  Neither prospective role for VETF has yet been confirmed. 
 
4.1.d.  E8R Gene: 
The specific role of the VACV E8R gene has not yet been accurately determined 
although several studies have been conducted.  E8R was predicted to contain two 
transmembrane domains and was first investigated as a potential membrane protein 
involved in ER wrapping (Tolonen, et al., 2001).  E8R was shown to localize to DNA 
replication sites and to be concentrated in the ER surrounding the replication site.  Based 
on these findings E8R was suggested to be an ER-resident membrane protein that may 
bind newly synthesized VACV DNA and aid in ER wrapping (Tolonen, et al., 2001).  
Due to the suggested role of aiding in ER wrapping, the E8R gene was further 
investigated leading to conflicting reports on the characteristics of E8R and its role in the 
VACV life cycle.   
Doligo et al. further characterized the E8R gene product as being made early in 
infection and as being associated with the ER membrane as early as 1 hour post-
infection.  E8 was also shown to associate with the membranes of immature virions (IV), 
intracellular mature virus (IMV), and with viral cores.  E8 is phosphorylated in vitro by 
F10 kinase, a process that was shown to reduce the binding of DNA to E8.  Based on 
this information it was speculated that E8R might mediate the binding of DNA to ER 
membranes leading to the enclosure of the replication site by ER membranes (Doglio, et 
al., 2002). 
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The role of E8R was also investigated using ts-mutants; the results from these 
experiments are inconsistent with the characterization by Doligo et al.  Kato et al. showed 
E8R to be expressed late in infection, contrary to previous reports.  Upon investigation of 
the promoter and gene, sequences consistent with a late gene promoter were found.  The 
coding sequence was also shown to contain two early transcription termination sequences 
further supporting the conclusion that E8 is a late protein (Doglio, et al., 2002, Kato, et 
al., 2007). 
Ts-mutants in the E8R gene synthesized DNA and proteins at the same level for 
both permissive and non permissive temperatures, indicating that an absence or decrease 
of E8 protein did not affect the DNA factories, as would have been expected if E8 had a 
role in them.  Ts-mutants and wild type viruses produced similar amounts of particles per 
cell at permissive and non-permissive temperatures, but the infectivity of the ts-mutant 
particles at the non-permissive temperature was greatly decreased.  The infectivity of ts-
mutants grown at non-permissive temperatures was reduced 35 fold compared to the 
same virus grown at permissive temperatures (Kato, et al., 2007).   
Virions grown at non-permissive temperatures were able to enter cells; however, 
the virions were defective in early viral transcription, producing only 10% the amount of 
RNA compared to wild type.  Although the virions were defective in early transcription, 
their extracts were able to synthesize RNA transcripts similar to wild type indicating that 
the mutant virions contain all the necessary factors for transcription.  The E8R mutants 
resemble L3L ts-mutants in that both form virus particles indistinguishable from wild 
type, but that are deficient in early transcription within the core.  Contrary to the 
conclusions of Dolgio et al. and Tolonen et al., Kato et al. concluded that E8 appears to 
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have a role in the virion core structure which impacts core transcription (Kato, et al., 
2007).  No definitive role for E8 has been established and an inducible E8R VACV 
mutant has not yet been generated. 
 
4.1.e.  F17R Gene: 
F17R, also referred to as F18 or p11, is one of the most abundant core proteins, 
accounting for 11% of the virion mass (Sarov and Joklik, 1972).  F17 binds strongly to 
DNA and has been characterized as a DNA-binding protein (Kao and Bauer, 1987, Kao, 
et al., 1981).  In 1991, an inducible F17R recombinant was generated using the lac 
operon.  LacI was constitutively expressed and the lac operator inserted between the 
gene’s translational start site and its promoter.  This recombinant was unable to replicate 
in the absence of inducer (IPTG) (Zhang and Moss, 1991a).  The inducible F17R mutant 
was the first conditional-lethal VACV mutant generated using any operon system.   In the 
absence of inducer, cleavage of the major virion protein precursors (p4a and p4b) was 
inhibited and morphogenesis was blocked at an intermediate stage (Zhang and Moss, 
1991b).  Further investigation determined that in the absence of F17 no typical mature 
virions are formed, and immature virions with unusual internal membranes and aberrant 
noninfectious mature virions are produced (Wickramasekera and Traktman, 2010).   
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4.2.  MATERIALS AND METHODS 
 
4.2.a.  Research Design: 
Inducible recombinant VACVs were designed by incorporating tetO sequences 
into the promoters for the selected essential late genes (A3L, A6L, A7L, D6R, E8R, and 
F17R) and inserting the tetR gene (under a constitutive promoter) into the VACV 
genome.  The resulting recombinant VACVs were expected to only be able to replicate in 
the presence of tetracyclines.   
 
Six recombinant VACVs have been designed: 
1. viA3L (for VACV Inducible A3L) expressing TetR constitutively and having the 
A3L gene under the control of the tet-responsive A3L promoter (PiA3L).   
2. viA6L (for VACV Inducible A6L) expressing TetR constitutively and having the 
A6L gene under the control of the tet-responsive P11 (F17R) promoter (Pi11).   
3. viA7L (for VACV Inducible A7L) expressing TetR constitutively and having the 
A7L gene under the control of the tet-responsive P11 (F17R) promoter (Pi11).   
4. viD6R (for VACV Inducible D6R) expressing TetR constitutively and having the 
D6R gene under the control of the tet-responsive D6R promoter (PiD6R).   
5. viE8R (for VACV Inducible E8R) expressing TetR constitutively and having the 
E8R gene under the control of the tet-responsive E8R promoter (PiE8R).   
6. viF17R (for VACV Inducible F17R) expressing TetR constitutively and having 
the F17R gene under the control of the tet-responsive F17R promoter (Pi11).   
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4.2.b.  Tet-Responsive Late Promoter Design: 
Late VACV promoter sequences are less conserved than early promoters, but 
have a very distinct initiator sequence.  Late VACV promoters commonly consist of a 20 
bp long T-run, a 6 bp spacer region, and a highly conserved TAAAT initiator sequence 
(Davison and Moss, 1989).  To make a promoter tet-responsive the operator sequence is 
added downstream of the initiator. The P11 promoter of VACV has previously been used 
as a lac-responsive and tet-responsive promoter (Fuerst, et al., 1989, Weber, et al., 2007) 
To make the P11 promoter tet-responsive, the tetO2 sequence (TCCCTATCAGTGATAG-
AGA) was inserted downstream of the initiator to generate Pi11 (Weber, et al., 2007).  The 
synthetic PE/L promoter has also successfully been made tet-responsive by inserting the 
tetO2 sequence after the initiator.   To transform the promoters of the chosen essential late 
genes into tet-responsive promoters, their promoters and intergenic regions were studied.     
The A3L intergenic region is 52 bp and is expected to contain only the late 
promoter for the A3L gene.  The entire intergenic sequence was used for the A3L 
promoter to ensure the entire promoter would be used in its natural state.  The tet O2 
sequence was then inserted after the putative late initiator sequence (TAAATA) 
generating PiA3L (Figure 4-1 and Table 4-1).   
 
 
 
 
  
Figure 4-1.  A3L Region of the Vaccinia Virus G
surrounding genes are shown, with bp sizes of the genes 
(above). 
 
The A6L intergenic region is only 23 bp, 
poxvirus promoter length, 
the upstream gene.  When the intergenic region was carefully inspected, the sequence 
contained several possible late initiator sequences and the sta
be identified with confidence
promoter was removed and
gene (Figure 4-2 and Table 4
 
Figure 4-2.  A6L Region of the 
surrounding genes are shown, 
(above).  A negative size indicates an overlap between genes
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enome.  The A3L gene and 
(below) and intergenic regions
 
and since it is shorter than the typical 
it is likely that the start of the A6L promoter is located within 
rt of the promoter could not 
; therefore the intergenic region containing the natural
 the Pi11 promoter was used to control transcription of the 
-1). 
Vaccinia Virus Genome.  The A6L gene and 
with bp sizes of the genes (below) and intergenic regions
. 
 
 
 A6L 
A6L 
 
 
  
The A7L intergenic region (53 bp)
gene and the A8R gene.  It was not possible to accurately identify and separate the 
sequences for the two promoters;
transcription of the A7L gene
in the viral genome to prevent interfering with transcription of the 
natural promoter initiator sequence was changed from TAAAT to TAAGG to prevent 
transcription initiator from that site
 
Figure 4-3.  A7L Region of the 
surrounding genes are shown, 
(above). 
 
D6R has an intergenic region of 40 bp that 
promoter for the D6R gene.  The entire 
promoter of D6R and the 
sequence (TAAATA) to generate the 
Table 4-1). 
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 possibly contains promoters for both the 
 therefore the Pi11 promoter was used to control the 
 (Figure 4-3 and Table 4-1).  The intergenic region was kept 
A8R gene and the 
 (Table 4-1). 
Vaccinia Virus Genome.  The A7L gene and 
with bp sizes of the genes (below) and intergenic regions
is expected to contain 
D6R intergenic sequence was used
tet O2 sequence was inserted after the putative late 
tet-responsive D6R promoter PiD6R 
A7L 
A7L 
 
 
only the late 
 as the natural 
initiator 
(Figure 4-4 and 
  
Figure 4-4.  D6R Region of the 
surrounding genes are shown, 
(above). 
 
The entire intergenic sequence 
after the putative late initiator (TAAATA
Table 4-1).  The entire intergenic region, which only contains the promoter for 
used to ensure that the entire natural
 
Figure 4-5.  E8R Region of the 
surrounding genes are shown, 
(above). 
 
The natural promoter for the 
region of the F17R gene is 62 bp and contains both the promoter for the 
for the F16L gene (Figure 
tet-responsive F17R promoter
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Vaccinia Virus Genome.  The D6R gene and 
with bp sizes of the genes (below) and intergenic regions
of E8R (124 bp) with the tetO2 sequence inserted 
) was used to generate PiE8R (Figure 
 promoter for the gene was included.
Vaccinia Virus Genome.  The E8R gene and 
with bp sizes of the genes (below) and intergenic regions
F17R gene is the P11 promoter.  The intergenic 
F17R
4-6).  The previously designed Pi11 promoter was used as the 
 and 2 bp of the F17R promoter were repeated and included 
 
 
4-5 and 
E8R, was 
 
 
 
 gene and 
  
as part of the F16L promoter to ensure the entire F16R promoter remains in its natural 
state. 
Figure 4-6.  F17R Region of the 
surrounding genes are shown, 
(above).  A negative size indicates an overlap between genes
 
Table 4-1:  Essential Gene Tet
Essential 
VACV 
Gene 
Inducible 
Promoter 
Name 
A3L PiA3L 
A6L Pi11 
A7L Pi11 
D6R PiD6R 
E8R PiE8R 
F17R Pi11 
(PiF17R) 
a
 Initiator sequences are in bold; 
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Vaccinia Virus Genome.  The F17R gene and 
with bp sizes of the genes (below) and intergenic regions
. 
-Responsive Promoter Sequences.
 
Promoter Sequencea 
ATAAGATTGGATATTAAAATCACGCTTTCGAGTAAAAAC
TACGAATATAAATATCCCTATCAGTGATAGAGA
ATATAGTAGAATTTCATTTTGTTTTTTTCTATGCTA
ATCCCTATCAGTGATAGAGA 
ATATAGTAGAATTTCATTTTGTTTTTTTCTATGCTA
ATCCCTATCAGTGATAGAGA 
ATATATGCTCATATATTTATAGAAGATATCACATATC
ATATCCCTATCAGTGATAGAGA 
GTATAATCCCATTCTAATACTTTAACCTGATGTATTAGCA
TCTTATTAGAATATTAACCTAACTAAAAGACATAACATA
AAAACTCATTACATAGTTGATAAAAAGCGGTAGGATA
AATATCCCTATCAGTGATAGAGA 
ATATAGTAGAATTTCATTTTGTTTTTTTCTATGCTA
ATCCCTATCAGTGATAGAGA 
tetO2 sequences are underlined. 
 
 
 
 
TAAAT
TAAAT
TAA
TA
TAAAT
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4.2.c.  Construction of Transfer Vectors for viA3L, viA6L, viA7L, viD6R, viE8R, and 
viF17R: 
A series of cloning steps was used to build the transfer vectors based on existing 
plasmids and designed synthetic DNA sequences.  The final transfer vectors contain: (1) 
the selectable E. coli xanthine-guanine phosphoribosyl transferase (gpt) gene and the 
screening marker EGFP gene, as a fusion gene (gpt-EGFP) under control of the synthetic 
early/late promoter PE/L; (2) the repressor gene tetR under the synthetic early/late PE/L 
promoter (Chakrabarti, et al., 1997); (3) a tet-responsive promoter to direct the expression 
of the essential gene; and (4) a left border sequence (600 bp of the gene upstream of the 
essential gene) and a light border sequence (the first 600 bp of the essential gene or 
intergenic region) to serve as recombination sequences for homologous recombination. 
The SphI-XmaI fragment (containing the gpt-EGPF gene, tetR gene, and a spacer 
region) from pCH033 was cloned into the SphI-XmaI site of pCH051 (A3L), pCH052 
(A6L), pCH053 (A7L), pCH054 (D6R), pCH055 (E8R), and pCH056 (F17L) (synthetic 
plasmids containing the essential gene tet-responsive promoter, and respective left and 
right recombination sequences (obtained from DNA2.0, Menlo Park, CA).  This step 
generated the final transfer vectors: pCH057 (viA3L), pCH058 (viA6L), pCH059 
(viA7L), pCH060 (viD6R), pCH061 (viE8R), and pCH062 (viF17R) (Figure 4-7).   
 
  
Figure 4-7.  Construction 
pCH060, pCH061, and pCH062
vectors are depicted.  All final transfer 
under constitutive promoters
gene under a tet-responsive
border (LB) and right border (RB)
with the VACV genome to generate 
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of Final Transfer Vectors pCH057, pCH058, pCH059, 
.  The cloning step used to generate the final transfer 
vectors express the gpt-EGFP and 
.  Each transfer vector was designed to express the
 late promoter.  All of the genetic elements are 
 sequences, which direct homologous recombination
their respective recombinants. 
 
tetR genes 
ir essential 
flanked by left 
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4.2.d.  Generation of Recombinant Viruses: 
Homologous recombination was used to precisely insert the genetic elements 
between the Left and Right Borders of each of the final transfer vectors into the 
intergenic region between the essential and upstream genes, placing the inducible 
promoter in front of the essential gene.  The recombinant VACVs were generated by 
standard homologous recombination via transfection of the transfer vectors pCH057, 
pCH058, pCH059, pCH060, pCH061, or pCH062 into BS-C-1 cell monolayers infected 2 
h earlier at 0.05 PFU per cell with VACV strain Western Reserve (WR) clone 9.2.4.8 
(obtained from T. Yilma, University of California Davis).  Recombinant gpt-positive 
VACVs were plaque purified on BS-C-1 cells from transfection lysates using gpt 
selection medium (25 µg/ml mycophenolic acid, 250 µg/ml xanthine, and 15 µg/ml 
hypoxanthine) (Legrand, et al., 2004).  All recombinants were plaque-purified in the 
presence of inducer (1 µg/ml doxycycline).  Expression of EGFP was detected via 
fluorescence microscopy (Carl Zeiss Axio Observer D1) to ensure that the recombinant 
viruses were free of parental virus.  High-titer stocks were generated by infecting HeLa 
S3 cells with the recombinant VACVs at a multiplicity of infection (MOI) of 0.1.  
Infected cells were harvested 4 days post-infection by centrifugation at 200 × g for 10 
min.  Cells were then lysed by freezing and thawing, sonicated, and trypsinized.  Finally, 
cell lysates were clarified to remove contaminating cell debris by a second round of 
sonication and centrifugation at 500 × g for 10 min.  The overall genomic structure of 
each recombinant VACV was determined by restriction analysis and PCR analysis of 
viral DNA, which was purified using a small-scale method employing micrococcal 
nuclease (Lai and Chu, 1991). 
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4.2.e.  The Effect of Doxycycline Concentration on Plaque Size: 
The ability of the recombinant viruses to grow in the presence or absence of 
inducer (doxycycline) was first investigated by plaque assay.  Cell monolayers in six-well 
plates were infected at 40 PFU/well, in the presence of 0, 1, 10, 100, or 1000 ng/ml 
doxycycline; photographs and measurements of isolated VACV plaques were taken 40 h 
postinfection with an inverted microscope. For plaque size measurements, cells were 
stained with crystal violet (0.5% in 20% ethanol), and the diameters of plaques were 
measured under an inverted microscope (Carl Zeiss Axio Observer D1) with 
measurement-capable software (AxioVision).  Paired t-tests were used to determine the 
significance of doxycycline concentration on the plaque size of the different recombinant 
viruses and WR.  Unpaired t-tests were used to determine the difference of plaque sizes 
between the viruses.  All statistical tests were performed with the statistical software 
Prism (GraphPad Software Inc, San Diego, CA). 
 
4.2.f. The Effect of Tetracycline, Doxycycline, and Anhydrotetracycline on Plaque 
Size: 
The ability of the recombinant viruses to grow in the presence of different 
tetracyclines was investigated by plaque assay.  BS-C-1 cell monolayers in 12-well plates 
were infected at 20 PFU/well, in the presence 1 µg/ml of doxycycline, tetracycline, or 
anhydrotetracycline.  Photographs and measurements of isolated VACV plaques were 
taken 40 h postinfection with an inverted microscope. For plaque size measurements, 
cells were stained with crystal violet (0.5% in 20% ethanol), and the diameters of plaques 
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were measured under an inverted microscope (Carl Zeiss Axio Observer D1) with 
measurement-capable software (AxioVision).   
 
4.2.g.  Viral Titers with Varying Doxycycline Concentrations: 
BS-C-1 cells in 12 well plates were infected at an MOI of 0.01 with WR, viA3L, 
viA6L, viA7L, viD6R, viE8R, or viF17R.  After 1 h, virus was aspirated and DME/2.5% 
FBS with 1000, 100, 10, 1, or 0 ng/ml doxycycline was added.  Cells were collected 
either 0 h (immediately after the 1 h infection) or at 48 h post-infection.  The intracellular 
fraction of virus was collected: cells were removed from the wells, centrifuged at 300 x g 
for 10 min to pellet the cells, supernatant (containing extracellular virus) was removed 
and the cells were resuspended in 500 µl of DMEM. The intracellular fraction was 
processed and titered on BS-C-1 cells as previously described (Verardi, et al., 2001), in 
the presence of 1 µg/ml of doxycycline.  
  
4.3.  RESULTS 
4.3.a.  Construction of Recombinant Viruses: 
Recombinant viruses were successfully constructed and plaque purified.  PCR of 
viral DNA, purified by small-scale miccrococcal nuclease method, showed all 
recombinants to have the genetic elements correctly inserted into the VACV genome 
(data not shown).   
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4.3.b.  Plaque Assays and Plaque Size: 
All of the recombinant viruses display unique growth characteristics in response 
to doxycycline.  Overall, the recombinants viA6L, viA7L, viD6R, and viF17R all 
displayed a degree of dependence on doxycycline for viral plaque formation.  
Recombinant viA3L and viE8R did not (Figures 4-8 and 4-9).   
Recombinants that were dependent on doxycycline for plaque production 
produced abortive infections in the absence of doxycycline.  Infected cells could be 
detected by the expression of EGFP, but no plaques were formed after 48 h post-infection 
(Figure 4-10) or even after 1 week post-infection (data not shown).   
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Figure 4-8.  Viral Plaques in the Presence and Absence of Doxycycline.  Wells were 
infected with 50 PFU of virus and grown the presence of absence of 1 µg/ml doxyxycline 
(Dox), after approximately 48 h cells were stained with crystal violet. 
 
  
Figure 4-9.  The Effect of Dox
presence or absence of 1 
with crystal violet, a representative image from each treatment is shown above.
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ycycline on Plaque Size.  Virus was grown in the
µg/ml doxycycline (Dox) for 40 h.  After 40 h cells were stained 
 
 
 
  
Figure 4-10.  Abortive Infection in the Absence of Dox
is shown in the images, the infected cell 
the fluorescence and combined images).  The singe infected cell is not detectable in the 
brightfield image, as the expression of EGFP is the only indication 
within the cell. 
The recombinant viA3L 
doxycycline concentrations
For example, at 1000 ng/ml, the average plaque 
compared to 645.6 µm for WR.  However, this difference was observed even in the 
absence of doxycycline, where the average plaque radius for viA3L was 582.4.3 µm, 
compared to 653.1 µm for WR, perhaps indicating that viA3L does
protein at wild type levels.
viE8R shows some dependence on dox
decreased at 1 ng/ml and 0
However, even with no dox
plaques.  At 100 ng of dox
significantly. 
Recombinants viA6L, viA7L, viD6R, and viF17R all were unable to form plaques 
in the absence of doxycyc
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ycycline.  A single infe
is detected by the expression of EGFP (seen in 
that virus is present 
is not dependent on doxycycline for replication
 tested, viA3L produced slightly smaller plaques than WR
radius for viA3L was 563.3 µm, 
 not express the A3 
 
ycycline for replication, since 
 ng/ml doxycycline concentration (Figure 4-11 and Table 4
ycycline present, viE8R was able to replicate and produce 
ycycline the plaque radius of WR and viE8R did
line (Figure 4-11 and Table 4-2).  viA6L formed plaques at 
 
cted cell 
, but at all 
.  
plaque size 
-2).  
 not differ 
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1000, 100, and 10 ng/ml of doxycycline that were not significantly different in size.  
However, at 1 and 0 ng/ml doxycycline no plaques formed, only abortive infections 
occurred.  At 1000 ng/ml doxycycline the average plaque radius of viA6L (628.2 µm) 
was not significantly different from WR (636.8 µm). 
viA7L is also dependent on doxycycline for plaque formation; the virus was able 
to form plaques at 1000, 100,10, and 1 ng/ml of doxycycline, but only abortive infections 
were seen in the absence of doxycycline (Figure 4-11 and Table 4-2).  Plaques produced 
in the presence of 1000, 100 or 10 ng/ml doxycycline did not differ in size, but plaques 
produced at 1 ng/ml doxycycline were significantly smaller at 216.6 µm average radius.  
Also, at 1000 ng/ml doxycycline the average plaque size produced by viA7L was 
significantly smaller (559.9 µm) than WR (636.8 µm). 
viD6R has growth characteristics similar to viA7L, in that it produces plaques at 
1000, 100, 10 and 1 ng/ml doxycycline, but does not produce any plaques in the absence 
of doxycycline (Figure 4-11 and Table 4-2).  The plaque sizes produced by viD6R at 100 
ng/ml are significantly larger than at 1000, 10 or 1 ng/ml.  A doxycycline concentration 
of 1 ng/ml produces significantly smaller plaques (average of 320.1 µm) than at 1000, 
100, or 10 ng/ml.  The average plaque size of viD6R at 100 ng/ml doxycycline (628.4 
µm) is not significantly different than the plaques produced by WR. 
The recombinant viF17R responded to doxycycline differently than all other 
recombinants.  The virus appeared to be attenuated; plaques were only produced at 1000 
and 100 ng/ml of doxycycline, and the plaques were much smaller than plaques formed 
by any of the other viruses at these concentrations (Figure 4-11 and Table 4-2).  The 
  
average plaque sizes were 242.7
formed at 10, 1 and 0 ng/ml 
 
Table 4-2:  Average Plaque Radius (µm) of R
Vaccinia Viruses under Different Doxycycline C
Doxycycline 
Concentration 
(ng/ml) WR 
1000 645.4 
100 616.9 
10 627.1 
1 641.5 
0 653.1 
a
 AB = abortive infection.
 
Figure 4-11.  The Effect of Doxycycline C
doxycycline concentration on plaque radius is depicted.  
40 PFU/well of virus and allowed to grow in the presence of 0, 1, 10, 100, or 1000 ng/ml 
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 µm and 281.1 µm respectively.  No plaques were 
doxycycline.   
ecombinant and Wild
oncentrations
Average Plaque Radius (µm)a 
viA3L viA6L viA7L viD6R viE8R
563.3 628.2 559.9 566.4 650.4
591.9 645 570.9 628.4 626.1
579 593.5 590 559.5 627.3
611.6 AB 216.2 320.1 603.8
582.4 AB AB AB 554.2
 
oncentration on Plaque Size
BS-C-1 cells were infected with 
-type (WR) 
. 
 viF17R 
 242.7 
 281.1 
 AB 
 AB 
 AB 
 
.  The effect of 
  
doxycycline for 40 h.  At 40 h
0.0001 (paired t-test). 
 
4.3.c.  Effect of Doxycycline, Tetracycline, and Anhydrotetracycline on Plaque Size:
No significant difference
different recombinant viruses and WR 
tetracycline, or anhydrotetracycline
Figure 4-12.  The Effect of T
different tetracyclines on plaque radius is depicted.  BS
PFU/well of the virus and allowed to grow in t
tetracycline (Tet), anhydrotetracycline (At
significant differences were observed among
SEM.   
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 plaque sizes were measured.  Error bars = 
s in the size of plaques were observed among 
grown in the presence of 1 µg/ml 
 (Figure 4-12). 
etracyclines (1 µg/ml) on Plaque Size.  The effect of 
-C-1 cells were infected with 20 
he presence of doxycycline
c) (1 µg/ml), or no tetracyclines (Tcs).  No 
 the different tetracyclines.  Error bars
SEM.  *** = p < 
 
the 
doxycycline, 
 
 (Dox), 
 = 
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4.3.d.  Viral Titers with Varying Doxycycline Concentrations: 
With the exception of viD6R, the viral titers obtained 48 h after infection of BS-
C-1 cells at an MOI of 0.01 in the presence of varying doxycycline concentrations 
reflected the plaque sizes that were observed in the single plaque analysis (Figures 4-13 
and 4-14).  As expected, WR, viA3L, and viE8R showed no dependence on doxycycline 
for viral replication, while the titers of viA6L, viA7L, and viF17R were dependent on 
doxycycline.  Recombinant viA6L had a high titer for 1000, 100, and 10 ng/ml 
doxycycline, which dropped rapidly from 8.5 x 106 PFU/ml at 10 ng/ml to 40 PFU/ml at 
1 ng/ml doxycycline and remained close to that level at 0 ng/ml doxycycline. viA7L 
showed a more gradual decrease in titer.  The titer dropped from 7.2 x 106 PFU/ml at 10 
ng/ml doxycycline to 1.9 x 104 PFU/ml at 1 ng/ml and finally to 0 PFU/ml in the absence 
of doxycycline.  The results for viA6L and viA7L mimic what was seen when observing 
plaque size.   
The titers of viD6R did not follow the observation of plaque size.  When 
measuring plaque size, no plaques were seen in the absence of doxycycline, however the 
titer of viD6R at 0 ng/ml was 1.05 x 105 PFU/ml, much higher than that observed for 
viA7L or viA6L (both of which also did not produce plaques in the absence of 
doxycycline).  The attenuation of viF17R was also apparent in the titers.  Although no 
viral plaques were observed at 10, 1, or 0 ng/ml doxycycline, the viral titers at 10 and 1 
ng/ml doxycycline were increased in comparison to the absence of doxycycline.  
  
Figure 4-13.  The Effect of D
in 12 well plates were infected at an MOI of 0.01 for 1 
(Initial Titer) or allowed to grow in the presence of 0, 1, 10
doxycycline (Dox) for 48 
SD. 
 
Figure 4-14.  The Effect of D
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(Initial Titer) or allowed to grow in the presence of 0, 1, 10, 100, or 1000 ng/ml 
doxycycline (Dox) for 48 h.  Intracellular virus was processed and titered.  Fold change 
was calculated as the end titer (48 h) compared to the initial (input) titer (0 h). 
 
4.4.  DISCUSSION 
Both viA3L and viE8R display little or no dependence on the presence of 
doxycyline for replication.  This result was unexpected as there is evidence of both genes 
being critical to viral replication.  Both viA3L and viE8R utilize their natural promoters 
with the operator sequence inserted prior to translational start site of the essential gene.  
The exact location of the promoter sequences for both A3L and E8R are unknown and the 
operators may have been inserted in a less than ideal location, causing the gene to be 
insufficiently repressed. 
The recombinant viF17R was attenuated; replication even in the presence of 1 
µg/ml doxycycline was very low compared to all other recombinants and WR.  This 
effect was seen previously using the lac operon system to control F17R gene expression 
(Zhang and Moss, 1991a).  In the lac inducible F17R virus the intergenic region of F17R 
was not modified except to insert the operator sequence.  When creating the viF17R 
recombinant, the intergenic region was split at the end of the F17R promoter by the 
inserted genetic elements.  This left only 34 bp of the intergenic region for the F16L 
promoter, if the entire F16L promoter was not located within the 34 bp, it may have 
affected the expression of F16L.  In previous studies F16L was found to be nonessential 
to viral replication in cell culture and this modification to viF17R should not have 
decreased viral replication (Senkevich, et al., 2011).  In addition, the viF17R gene 
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product, p11, may be required in such high amounts that any modification of this strong 
late promoter decreases transcription, causing viral replication to also be reduced.   
Although viF17R plaque formation is prevented even when 10 ng/mL of 
doxycycline is present, the inability of the virus to replicate at levels comparable to WR 
even at high doxycycline concentrations makes this recombinant a less than ideal vaccine 
candidate.  The low rate of replication would cause the vaccine to be attenuated and to 
produce an inferior immune response compared to a non-attenuated recombinant.   
The recombinant viA6L replicated at levels similar to WR at 1000, 100, and 10 
ng/ml of doxycycline.  No replication was seen at 1 ng/ml doxycycline.  These growth 
characteristics are highly desirable for a doxycycline dependent vaccine.  This is the first 
successful VACV containing an inducible A6L gene.  Thus, the viA6L recombinant may 
also be useful in clarifying the specific role of this gene.  The arrangement of genomic 
elements used for this system is unique in that all elements were inserted into the 
intergenic region of the gene, this did not require moving the gene of interest to a 
different location within the genome, as is frequently done when using the lac operon 
system.  Recombinant VACV encoding an inducible viA6L gene had previously been 
attempted using the lac operon.   However, replacing the A6L promoter with an inducible 
promoter or inserting an inducible copy of the A6L gene and replacing the A6L gene with 
a GFP cassette both failed to generate an inducible A6L mutant (Meng, et al., 2007).  The 
replacement of the A6L gene with a GFP cassette may have failed to produce a viable 
recombinant because removing the A6L gene also removes the last 4 bp of the A5R gene 
(RNA polymerase 19kDa subunit).  It is unknown why replacing the A6L promoter with 
an inducible promoter also failed to generate an inducible mutant.  It is possible that the 
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gene was unable to be induced to a high enough level to meet the requirement of A6L 
using the lac operon system (Meng, et al., 2007).   
The recombinant viA7L is also dependent on doxycycline for viral replication.  
This virus was able to replicate at 1000, 100, 10, and 1 ng/ml doxycycline, but was 
unable to replicate in the absence of doxycycline.  Although viA7L was able to replicate 
in the presence of only 1 ng/ml doxycycline, its replication was greatly reduced compared 
to the higher doxycycline concentrations.  An inducible A7L mutant, previously 
generated using the lac operon system, was shown to replicate at levels lower than WR 
(Hu, et al., 1998).  Our viA7L recombinant appears to replicate at levels much closer to 
WR than the lac operon mutant previously generated.  This may be due to the different 
operon systems used and differences in the genetic setup of the viruses.  In the lac operon 
mutant, the A7L gene is moved to the HA (non-essential) region of the VACV genome 
and placed under the control of a T7lacO promoter and the original A7L gene is replaced 
by a neomycin resistance gene.  A T7 RNA polymerase gene is inserted into VACV in a 
non-essential region (TK region) under the control of a P11lacO promoter.  This setup 
has two lacO-regulated steps, the IPTG dependent transcription of the T7 RNA 
polymerase and the IPTG/T7 RNA polymerase dependent transcription of A7L.  The 
system used to make our recombinants only involves one tetO-regulated step and does 
not involve changing the location of the essential genes, the combination of which 
appears to allow the viA7L recombinant to replicate at levels close to WR.   
Plaque size does not necessarily correlate to viral replication.  While plaque size 
is a good correlate for some of the recombinants, it is not true for all recombinants. The 
recombinant viD6R, similar to viA7L, formed plaques in the presence of 1000, 100, 10, 
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or 1 ng/ml doxycycline, although at 1 ng/ml doxycycline plaques were significantly 
smaller.  Interestingly, viD6R was unable to produce plaques in the absence of 
doxycycline, but the virus titer of viD6R in the absence of doxycycline did increase 
(compared to the initial or input titer), although it was still severely reduced compared to 
viD6R grown in the presence of doxycycline.  These results are similar to those generated 
using the lac operon system to control the A7L gene.  In the absence of inducer (IPTG) no 
plaques formed but the virus titer did increase slightly (Hu, et al., 1996).  
Tetracyclines are a class of broad spectrum antibiotics.  This class includes 
naturally occurring antibiotics such as tetracycline, and synthetic tetracyclines such as 
doxycyclines.  Three different tetracyclines (tetracycline, doxycycline, and 
anhydrotetracycline) were tested for their effect on viral replication of the recombinants.  
Typically tetracycline or doxycycline are used as inducers of tet operon systems.    
Anhydrotetracycline is known to bind TetR with 35-fold higher affinity than tetracycline 
(Degenkolb, et al., 1991).  Viruses treated with different tetracyclines (doxycycline, 
tetracycline, and anhydrotetracycline) at a concentration of 1 µg/ml all produced plaques 
of similar size.   While this is strongly indicative that the different tetracyclines do not 
have an effect on viral replication, this cannot be definitively concluded without the 
testing of viral titers.   
The observation that anhydrotetracycline does not increase the plaque size of the 
recombinant viruses in comparison to equal concentrations of doxycycline suggests that 1 
µg/ml of doxycycline is sufficient to induce maximum expression levels of the essential 
gene products and that the apparent attenuation of viF17R is not due to insufficient levels 
of inducer.   
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The goal of this research was to develop recombinant VACVs in which viral 
replication can be controlled through the addition/removal of tetracyclines.  By placing 
the A6L, A7L, D6R, and F17R genes under the control of the tet operon, inducible viruses 
were generated.  Each recombinant responds uniquely to doxycycline.  Based on the 
current analysis of the recombinants the viA6L virus appears to have the most desirable 
growth characteristics for VACV vectors.   The ability of viA6L to replicate at relatively 
low doxycycline concentrations (10 ng/ml) at a rate similar to wild type would allow the 
antibiotic dose given with the vaccine to be kept at a low and safe level for the vaccine 
recipient.  The abrupt cease of viral replication between 10 ng/mL and 1 ng/mL that 
viA6L displays is also a desirable trait in a doxycycline dependent vaccine.  If the 
vaccine can be induced with a low dose of doxycycline, when treatment is stopped the 
doxycyline concentration within the body should fall to the critical concentration quickly, 
rapidly stopping virus replication.   Similarly, viA7L is also a good vaccine candidate; 
however, this virus did replicate at reduced levels at 1 ng/ml doxycycline.  For replication 
to be induced at wild-type levels, 10 ng/ml doxycycline had to be used.  This suggests 
that for a good take to occur upon vaccination, viA7L would require a dose of 
doxycycline similar to A6L.  However, viral replication could be more difficult to stop, 
as 1 ng/ml doxycycline would be sufficient to induce the replication of viA7L.  If an 
adverse event occurs after vaccination once doxycycline treatment is stopped, the level 
within the body would have to decrease to below 1 ng/ml (rather than to below 10 ng/ml 
for viA6L) to stop viral replication and the adverse event.   
The recombinant viD6R appears to be a good vaccine candidate based on the 
plaque size assays, which show no evidence of viral replication in the absence of 
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doxycycline.  However, the viral titers of viD6R do increase even in the absence of 
doxycycline, raising the question of whether this gene would be ideal for vaccine and 
therapy vectors.   
While viF17R was inducible by tetracyclines, it appears to be attenuated which is 
not ideal for smallpox vaccination.  This recombinant was unable to replicate at levels 
similar to wild type even in the presence of high levels of inducer.  Recombinant viA3L 
and viE8R were not dependent on tetracyclines for replication, and in their current state 
are not good vaccine vector candidates.  However, this does not indicate that these genes 
may not be useful for controlling VACV replication.  There is strong evidence suggesting 
that both viA3L and viE8R are essential to VACV replication.  As mentioned before, the 
tetO sequences may have been inserted in a non-ideal location, allowing leaky or full 
expression of the gene.  It would be interesting to test whether viral replication would be 
controlled if the Pi11 promoter was used in place of the natural promoters. 
This work also suggests that more knowledge is needed about VACV promoters 
to be able to utilize natural VACV promoters in the control of gene expression.  In this 
research three natural promoters and three Pi11 promoters were used to control gene 
expression.  All of the viruses that utilized the Pi11 promoters were successful in 
producing tetracycline dependent recombinants (viA6L, viA7L, viF17R), whereas only 
one of the viruses that utilized a natural promoter with a tetO sequence was inducible 
(viD6R).  This may suggest that incorporation of the tetO sequence after the TAAATA 
initiator may not be ideal for every late VACV promoter or that unrecognized sequences 
within the promoters are acting as initiator sequences.   
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DISCUSSION AND FUTURE DIRECTIONS 
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Four successful inducible recombinant VACVs were generated (viA6L, viA7L, 
viD6R, and viF17R) that have many potential uses.  The same strategy could be used for 
the development of safer, new generation smallpox vaccines, replacing ACAM2000.  
They could also be used for the development of new generation viral vectors for both 
human and animal vaccines, and for oncolytic vectors.  They would provide a safety 
mechanism that would benefit not only the recipients of the vaccine or therapy, but also 
personnel administering the vectors (e.g., vaccinators) and contacts of the 
vaccine/therapy recipients. 
Another important potential use of the inducible VACVs would be to replace the 
TetR with a reverse TetR gene, thus creating a repressible VACV.  Mutagenesis studies 
have shown that the response of the TetR repressor can be reversed, causing TetR to act 
as an inducible repressor.  A variety of single and multiple mutations in the tetR gene are 
able to produce this phenotype.  The reverse form of the protein, revTetR, is only able to 
bind to the operator sequence and block transcription in the presence of tetracyclines 
(Gossen, et al., 1995, Resch, et al., 2008, Scholz, et al., 2004).  While different 
tetracyclines can be used with the TetR repressor, the effect of tetracyclines on revTetR 
varies greatly (Gossen, et al., 1995).  The revTetR repressible system is currently being 
adapted to the VACV system (Titong and Verardi, unpublished data). 
The repressible VACVs would have similar applications as the inducible VACVs, 
but instead of requiring tetracyclines for viral growth, tetracyclines would stop viral 
replication.  A repressible system would be especially beneficial in animal vaccines, such 
as the oral rabies vaccine.  The oral rabies vaccine, which is composed of a VACV 
vector, is used across the United States to vaccinate wildlife against rabies.  There are 
  73 
currently 16 states distributing the vaccines in baits for wildlife (Slate, et al., 2009).  The 
baits are composed of a plastic packet containing the vaccine and coated in fishmeal to 
attract animals.  Once an animal bites the bait the packet of vaccine is broken and the 
vaccine leaks into the mouth, resulting in viral replication and immunization of the 
animal (Slate, et al., 2005).  Although oral rabies vaccination programs are careful of 
where baits are dropped, inevitably people come in contact with the baits and the VACV 
vaccine vector they carry.  One such incident occurred in Pennsylvania in 2009 when a 
dog brought its owner a ruptured vaccine bait.  The owner had cuts on her hands and 
developed a VACV infection from handling the bait.  As the owner was on 
immunosuppressive medication for inflammatory bowel disease, treatment with VIGIV 
(Vaccinia Immune Globulin Intravenous) and investigational antiviral agents were 
required to clear the VACV infection.  However, she was not able to remain off her 
immunosuppressive medication for an extended period, making her treatment difficult 
(Centers for Disease Control and Prevention, 2009).  If a repressible VACV had been 
used in the rabies vaccine the woman could have been treated with tetracyclines to stop 
the VACV infection and may not have needed to be removed from her medication. 
The inducible VACV generated have many practical uses and will hopefully 
allow VACV to be utilized more frequently as a vector to develop life-saving vaccines 
and therapeutics.   
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